{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:26Z","timestamp":1791475346791,"version":"4.3.4"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF), one of the largest unmet medical needs, is characterized by high morbidity and mortality and a lack of effective treatments. Numerous studies suggest that the potential contribution of dysfunctional metabolism to HFpEF, emphasizing the possible role of lipids, especially lipoproteins, in the disease's initiation and progression. Changes in circulating plasma lipids appear to play a role in mediating the pathophysiological processes that may contribute to the development of HFpEF through an imbalance in the circulating lipid supply, cardiac fat uptake, and fatty acid metabolism. This metabolic mismatch results in the accumulation of harmful lipid intermediates within the myocardium. This process, known as lipotoxicity, contributes to diastolic dysfunction. Furthermore, altered plasma lipid levels can potentiate systemic inflammatory responses, endothelial dysfunction, and myocardial fibrosis. Understanding the impact of lipid metabolism on these underlying mechanisms is emerging as a novel avenue for preventing and treating HFpEF. The intricate relationship between HFpEF and lipid metabolism may involve multifaceted factors, including insulin sensitivity and adipose tissue inflammation. Here, we have comprehensively analysed the evidence-based pathophysiological impact of broader lipid abnormalities [including very low-density lipoprotein (VLDL) and low-density lipoprotein] on HFpEF development. Furthermore, drawing on foundational studies in related metabolic disorders, we propose a novel hypothesis regarding the potential, yet underexplored role of electronegative VLDL (V5), a particularly harmful subfraction of VLDL, as a future therapeutic target in HFpEF.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1885850","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:43:39Z","timestamp":1785840219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cellular basis of HFpEF: contributions of abnormal lipids"],"prefix":"10.3389","volume":"13","author":[{"given":"Huan-Hsing","family":"Chiang","sequence":"first","affiliation":[{"name":"Molecular Cardiology Research Laboratories, Vascular and Medicinal Research, The Texas Heart Institute at Baylor College of Medicine","place":["Houston, TX, United States"]},{"name":"School of Medicine, Texas Tech University Health Sciences Center","place":["Lubbock, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Akyol","sequence":"additional","affiliation":[{"name":"Molecular Cardiology Research Laboratories, Vascular and Medicinal Research, The Texas Heart Institute at Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Child-Care, College of Humanities and Social Sciences, National Pingtung University of Science and Technology","place":["Pingtung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Hochman-Mendez","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Research Department, The Texas Heart Institute at Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelmotagaly","family":"Elgalad","sequence":"additional","affiliation":[{"name":"Center for Preclinical Surgical & Interventional Research, The Texas Heart Institute at Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Woodside","sequence":"additional","affiliation":[{"name":"Molecular Cardiology Research Laboratories, The Texas Heart Institute at Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Molecular Cardiology Research Laboratories, Vascular and Medicinal Research, The Texas Heart Institute at Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1532-5415.1982.tb01983.x","article-title":"Left ventricular function in hospitalized geriatric patients","volume":"30","author":"Luchi","year":"1982","journal-title":"J Am Geriatr Soc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/ehf2.14654","article-title":"An altered plasma lipidome-phenome network characterizes heart failure with preserved ejection fraction","volume":"11","author":"Jovanovic","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s10741-025-10518-x","article-title":"Obesity and inflammation in chronic and acute heart failure","volume":"30","author":"Cotter","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/ijms20092222","article-title":"Cholesterol-Lowering gene therapy prevents heart failure with preserved ejection fraction in obese type 2 diabetic mice","volume":"20","author":"Aboumsallem","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.numecd.2022.03.003","article-title":"Lipids and diastolic dysfunction: recent evidence and findings","volume":"32","author":"Daneii","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/ijo.2017.239","article-title":"The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity","volume":"42","author":"Rayner","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11897-022-00582-x","article-title":"Defining the phenotypes for heart failure with preserved ejection fraction","volume":"19","author":"Rucker","year":"2022","journal-title":"Curr Heart Fail Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.jacc.2017.09.006","article-title":"Biological phenotypes of heart failure with preserved ejection fraction","volume":"70","author":"Lewis","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/HCO.0000000000001113","article-title":"Obesity\/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials","volume":"39","author":"Verma","year":"2024","journal-title":"Curr Opin Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jchf.2018.06.006","article-title":"Fat, female, fatigued: features of the obese HFpEF phenotype","volume":"6","author":"Lam","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7754\/Clin.Lab.2015.150730","article-title":"The investigation of a disintegrin and metalloproteinase with ThromboSpondin motifs (ADAMTS) 1, 5 and 16 in thoracic aortic aneurysms and dissections","volume":"62","author":"Gunes","year":"2016","journal-title":"Clin Lab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s12551-020-00742-0","article-title":"The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases","volume":"12","author":"Zhazykbayeva","year":"2020","journal-title":"Biophys Rev"},{"key":"B15","first-page":"BR187","article-title":"The effect of caffeic acid phenethyl ester on short-term acute myocardial ischemia","volume":"12","author":"Ince","year":"2006","journal-title":"Med Sci Monit"},{"key":"B16","doi-asserted-by":"publisher","first-page":"928232","DOI":"10.3389\/fphys.2022.928232","article-title":"Current understanding of molecular pathophysiology of heart failure with preserved ejection fraction","volume":"13","author":"Budde","year":"2022","journal-title":"Front Physiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3389\/fphys.2019.00638","article-title":"Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology","volume":"10","author":"Gevaert","year":"2019","journal-title":"Front Physiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/ijms25020794","article-title":"Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach","volume":"25","author":"Stoicescu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1161\/01.res.62.2.358","article-title":"Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle","volume":"62","author":"Brutsaert","year":"1988","journal-title":"Circ Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1152\/physrev.00017.2002","article-title":"Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity","volume":"83","author":"Brutsaert","year":"2003","journal-title":"Physiol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/eurheartj\/ehv132","article-title":"Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction","volume":"36","author":"Lim","year":"2015","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fphys.2018.00382","article-title":"Cardiac remodeling: endothelial cells have more to say than just NO","volume":"9","author":"Segers","year":"2018","journal-title":"Front Physiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"B26","first-page":"253","article-title":"Cardiac ruptures following myocardial infarction in medicolegal cases","volume":"7","author":"Akyildiz","year":"2007","journal-title":"Anadolu Kardiyol Derg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2014.00123","article-title":"Fibroblasts in fibrosis: novel roles and mediators","volume":"5","author":"Kendall","year":"2014","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cca.2016.10.017","article-title":"Update on ADAMTS13 and VWF in cardiovascular and hematological disorders","volume":"463","author":"Akyol","year":"2016","journal-title":"Clin Chim Acta"},{"key":"B29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.36660\/abc.20190111","article-title":"Pathophysiology and treatment of heart failure with preserved ejection fraction: state of the art and prospects for the future","volume":"114","author":"Lopes Fernandes","year":"2020","journal-title":"Arq Bras Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/labmed\/lmw022","article-title":"The role of ADAMTS1 and versican in human myocardial infarction: a postmortem study","volume":"47","author":"Pehlivan","year":"2016","journal-title":"Lab Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1172\/JCI108843","article-title":"Evidence for cardiomyopathy in familial diabetes mellitus","volume":"60","author":"Regan","year":"1977","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2337\/diab.40.5.605","article-title":"Increased matrix gene expression by glucose in rat neural connective tissue cells in culture","volume":"40","author":"Muona","year":"1991","journal-title":"Diabetes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/cvr\/cvad100","article-title":"Cardiac lipid metabolism, mitochondrial function, and heart failure","volume":"119","author":"Da Dalt","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.bbalip.2016.02.016","article-title":"Lipid metabolism and signaling in cardiac lipotoxicity","volume":"1861","author":"D'Souza","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1194\/jlr.R001115","article-title":"Myocardial lipid accumulation and lipotoxicity in heart failure","volume":"50","author":"Schulze","year":"2009","journal-title":"J Lipid Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/jcm13051195","article-title":"Myocardial metabolism in heart failure with preserved ejection fraction","volume":"13","author":"Henry","year":"2024","journal-title":"J Clin Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","article-title":"Lipid metabolism and toxicity in the heart","volume":"15","author":"Goldberg","year":"2012","journal-title":"Cell Metab"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","article-title":"Lipid use and misuse by the heart","volume":"118","author":"Schulze","year":"2016","journal-title":"Circ Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2337\/db24-0240","article-title":"PAK3 Exacerbates cardiac lipotoxicity via SREBP1c in obesity cardiomyopathy","volume":"73","author":"Chen","year":"2024","journal-title":"Diabetes"},{"key":"B41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1742-4658.2008.06806.x","article-title":"SREBPs: physiology and pathophysiology of the SREBP family","volume":"276","author":"Shimano","year":"2009","journal-title":"FEBS J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/01.cir.94.11.2837","article-title":"Fatty acid oxidation enzyme gene expression is downregulated in the failing heart","volume":"94","author":"Sack","year":"1996","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1042\/CS20210127","article-title":"Lipotoxicity: a driver of heart failure with preserved ejection fraction?","volume":"135","author":"Leggat","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/eurjhf\/hfq121","article-title":"Epidemiology and clinical course of heart failure with preserved ejection fraction","volume":"13","author":"Lam","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1161\/ATVBAHA.111.241984","article-title":"Insulin resistance: metabolic mechanisms and consequences in the heart","volume":"32","author":"Abel","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh","year":"2022","journal-title":"Circ Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1093\/cvr\/cvac166","article-title":"Cardiac metabolism in HFpEF: from fuel to signalling","volume":"118","author":"Capone","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"165744","DOI":"10.1016\/j.bbadis.2020.165744","article-title":"Mitochondrial dysfunction in metabolic and cardiovascular diseases associated with cardiolipin remodeling","volume":"1866","author":"El-Hafidi","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1073\/pnas.0630588100","article-title":"Triglyceride accumulation protects against fatty acid-induced lipotoxicity","volume":"100","author":"Listenberger","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s1050-1738(02)00152-4","article-title":"Mechanisms of lipoapoptosis: implications for human heart disease","volume":"12","author":"Listenberger","year":"2002","journal-title":"Trends Cardiovasc Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s11745-017-4285-7","article-title":"AMPK Prevents palmitic acid-induced apoptosis and lipid accumulation in cardiomyocytes","volume":"52","author":"Adrian","year":"2017","journal-title":"Lipids"},{"key":"B52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/CIRCRESAHA.120.317883","article-title":"Lipid profiles and heart failure risk: results from two prospective studies","volume":"128","author":"Wittenbecher","year":"2021","journal-title":"Circ Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1096\/fj.201700300R","article-title":"Lipotoxic very-long-chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes","volume":"32","author":"Law","year":"2018","journal-title":"FASEB J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"906272","DOI":"10.3389\/fphys.2022.906272","article-title":"Endothelial dysfunction in heart failure with preserved ejection fraction: what are the experimental proofs?","volume":"13","author":"Cornuault","year":"2022","journal-title":"Front Physiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.18632\/aging.101892","article-title":"Saturated fatty acid-crystals activate NLRP3 inflammasome","volume":"11","author":"Karasawa","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.3390\/cells11233843","article-title":"The role of oxidative stress in atherosclerosis","volume":"11","author":"Batty","year":"2022","journal-title":"Cells"},{"key":"B57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.51789\/cmsj.2021.1.e18","article-title":"Cardiometabolic HFpEF: mechanisms and therapies","volume":"1","author":"Schiattarella","year":"2021","journal-title":"Cardiometab Syndr J"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1125687","DOI":"10.3389\/fcvm.2023.1125687","article-title":"Inflammation as a therapeutic target in heart failure with preserved ejection fraction","volume":"10","author":"Peh","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/cvr\/cvae006","article-title":"Mitochondrial fatty acid oxidation is the major source of cardiac adenosine triphosphate production in heart failure with preserved ejection fraction","volume":"120","author":"Sun","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","article-title":"Ceramide is a cardiotoxin in lipotoxic cardiomyopathy","volume":"49","author":"Park","year":"2008","journal-title":"J Lipid Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/cells10010051","article-title":"role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair","volume":"10","author":"Lafuse","year":"2020","journal-title":"Cells"},{"key":"B62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10741-012-9340-0","article-title":"Mitochondrial dysfunction in heart failure","volume":"18","author":"Rosca","year":"2013","journal-title":"Heart Fail Rev"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.115.013894","article-title":"Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload","volume":"131","author":"Schiattarella","year":"2015","journal-title":"Circulation"},{"key":"B64","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-022-00972-6","article-title":"Signaling cascades in the failing heart and emerging therapeutic strategies","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis, mechanisms and cilinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","article-title":"Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies","volume":"115","author":"Sharma","year":"2014","journal-title":"Circ Res"},{"key":"B67","first-page":"158","article-title":"Aging and cardiac fibrosis","volume":"2","author":"Biernacka","year":"2011","journal-title":"Aging Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3920195","DOI":"10.1155\/2017\/3920195","article-title":"A review of the molecular mechanisms underlying the development and progression of cardiac remodeling","volume":"2017","author":"Schirone","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"B69","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tips.2018.11.004","article-title":"Mitochondrial permeability transition: a molecular lesion with multiple drug targets","volume":"40","author":"Briston","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10741-017-9634-3","article-title":"Protein kinase C and cardiac dysfunction: a review","volume":"22","author":"Singh","year":"2017","journal-title":"Heart Fail Rev"},{"key":"B71","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac metabolism in heart failure: implications beyond ATP production","volume":"113","author":"Doenst","year":"2013","journal-title":"Circ Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1152\/physiol.00004.2023","article-title":"Inflammatory mechanisms in heart failure with preserved ejection fraction","volume":"38","author":"Daou","year":"2023","journal-title":"Physiology (Bethesda)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.immuni.2015.08.023","article-title":"The cellular and molecular basis of translational immunometabolism","volume":"43","author":"Norata","year":"2015","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2018.07.030","article-title":"Krebs cycle reimagined: the emerging roles of succinate and itaconate as signal transducers","volume":"174","author":"Murphy","year":"2018","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"947147","DOI":"10.3389\/fimmu.2022.947147","article-title":"Inflamed adipose tissue: a culprit underlying obesity and heart failure with preserved ejection fraction","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s10517-017-3860-5","article-title":"Adipokine and cytokine profiles of epicardial and subcutaneous adipose tissue in patients with coronary heart disease","volume":"163","author":"Gruzdeva","year":"2017","journal-title":"Bull Exp Biol Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.mehy.2020.109821","article-title":"Why are cardiovascular diseases more common among patients with severe mental illness? The potential involvement of electronegative low-density lipoprotein (LDL) L5","volume":"142","author":"Akyol","year":"2020","journal-title":"Med Hypotheses"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1194\/jlr.M009258","article-title":"Proteomic analysis of electronegative low-density lipoprotein","volume":"51","author":"Bancells","year":"2010","journal-title":"J Lipid Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/biomedicines8120550","article-title":"Molecular and cellular mechanisms of electronegative lipoproteins in cardiovascular diseases","volume":"8","author":"Ke","year":"2020","journal-title":"Biomedicines"},{"key":"B81","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/biomedicines8080254","article-title":"Clinical significance of electronegative low-density lipoprotein cholesterol in atherothrombosis","volume":"8","author":"Chu","year":"2020","journal-title":"Biomedicines"},{"key":"B82","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1194\/jlr.M500481-JLR200","article-title":"Electronegative LDLs from familial hypercholesterolemic patients are physicochemically heterogeneous but uniformly proapoptotic","volume":"48","author":"Chen","year":"2007","journal-title":"J Lipid Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1161\/01.CIR.0000065220.70220.F7","article-title":"Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription","volume":"107","author":"Chen","year":"2003","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1161\/01.ATV.0000071350.78872.C4","article-title":"Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins","volume":"23","author":"Yang","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"9802","DOI":"10.1096\/fj.202000659R","article-title":"Increased APOE glycosylation plays a key role in the atherogenicity of L5 low-density lipoprotein","volume":"34","author":"Ke","year":"2020","journal-title":"FASEB J"},{"key":"B86","doi-asserted-by":"publisher","first-page":"993633","DOI":"10.3389\/fcvm.2022.993633","article-title":"Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: implications for disease progression and mechanistic insights","volume":"9","author":"Lee","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1038\/s41598-021-85502-0","article-title":"Electronegative very-low-density lipoprotein induces brain inflammation and cognitive dysfunction in mice","volume":"11","author":"Lin","year":"2021","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/jcm8081193","article-title":"Combined LDL and VLDL electronegativity correlates with coronary heart disease risk in asymptomatic individuals","volume":"8","author":"Shen","year":"2019","journal-title":"J Clin Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.imbio.2019.07.005","article-title":"Immunoregulatory effects of very low density lipoprotein from healthy individuals and metabolic syndrome patients on glial cells","volume":"224","author":"Li","year":"2019","journal-title":"Immunobiology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"12050","DOI":"10.1038\/s41598-017-11416-5","article-title":"Very-Low-Density lipoprotein of metabolic syndrome modulates gap junctions and slows cardiac conduction","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2016.11.033","article-title":"VLDL And LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis","volume":"388","author":"Lu","year":"2017","journal-title":"Cancer Lett"},{"key":"B92","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/ijms17010134","article-title":"VLDL From metabolic syndrome individuals enhanced lipid accumulation in atria with association of susceptibility to atrial fibrillation","volume":"17","author":"Lee","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2337\/dc11-1623","article-title":"Effects of electronegative VLDL on endothelium damage in metabolic syndrome","volume":"35","author":"Chen","year":"2012","journal-title":"Diabetes Care"},{"key":"B94","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.bbalip.2016.05.010","article-title":"Inflammatory intracellular pathways activated by electronegative LDL in monocytes","volume":"1861","author":"Estruch","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B95","doi-asserted-by":"publisher","first-page":"13992","DOI":"10.3390\/ijms232213992","article-title":"High-Density lipoprotein suppresses neutrophil extracellular traps enhanced by oxidized low-density lipoprotein or oxidized phospholipids","volume":"23","author":"Ohinata","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"0019","DOI":"10.34133\/research.0019","article-title":"Mass spectrometry imaging-based single-cell lipidomics profiles metabolic signatures of heart failure","volume":"6","author":"Ren","year":"2023","journal-title":"Research (Wash D C)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s12276-024-01309-9","article-title":"Altered lipid metabolism promoting cardiac fibrosis is mediated by CD34(+) cell-derived FABP4(+) fibroblasts","volume":"56","author":"Du","year":"2024","journal-title":"Exp Mol Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/j.jacc.2020.02.062","article-title":"Circulating ceramide 16:0 in heart failure with preserved ejection fraction","volume":"75","author":"Javaheri","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the heart failure association, the European heart rhythm association of the European Society of Cardiology, and the European society of hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B100","doi-asserted-by":"publisher","first-page":"167806","DOI":"10.1016\/j.bbadis.2025.167806","article-title":"Lipidomics and cardiovascular disease","volume":"1871","author":"Surendran","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12933-023-02057-2","article-title":"Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy","volume":"22","author":"Costantino","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.cir.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"B103","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2174\/1874467211205020272","article-title":"Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk","volume":"5","author":"Derosa","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes Mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes Mellitus - mechanisms, management, and clinical considerations","volume":"133","author":"L Wang","year":"2016","journal-title":"Circulation"},{"key":"B105","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12265-020-10026-3","article-title":"Immunomodulation in heart failure with preserved ejection fraction: current state and future perspectives","volume":"14","author":"Kessler","year":"2021","journal-title":"J Cardiovasc Transl Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41433-024-03410-9","article-title":"Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial","volume":"39","author":"Varughese","year":"2025","journal-title":"Eye (Lond)"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2337\/diacare.27.7.1647","article-title":"The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients","volume":"27","author":"Charbonnel","year":"2004","journal-title":"Diabetes Care"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1161\/CIRCULATIONAHA.108.798561","article-title":"Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase","volume":"119","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"B109","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.121.058301","article-title":"Impaired AMP-activated protein kinase signaling in heart failure with preserved ejection fraction-associated atrial fibrillation","volume":"146","author":"Tong","year":"2022","journal-title":"Circulation"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jacc.2024.05.065","article-title":"Effect of semaglutide on epicardial adipose tissue in type 2 diabetes: insights from the STOP (semaglutide treatment effect on coronary atherosclerosis progression)","volume":"84","author":"Manubolu","year":"2024","journal-title":"Randomized Trial. J Am Coll Cardiol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"101349","DOI":"10.1016\/j.jacbts.2025.101349","article-title":"Effect of semaglutide on epicardial adipogenesis and hiPSC-atrial cardiomyocytes new hope in targeting epicardial adipose tissue","volume":"10","author":"Gaborit","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"B115","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/cbf.3751","article-title":"Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice","volume":"40","author":"Martins","year":"2022","journal-title":"Cell Biochem Funct"},{"key":"B116","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/f1000research.28254.1","article-title":"Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature","volume":"10","author":"Techorueangwiwat","year":"2021","journal-title":"F1000Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"100385","DOI":"10.1016\/j.jacadv.2023.100385","article-title":"Impact of statin therapy in heart failure patients: results of a large real-world experience","volume":"2","author":"Anderson","year":"2023","journal-title":"JACC Adv"},{"key":"B118","doi-asserted-by":"publisher","first-page":"oeaf035","DOI":"10.1093\/ehjopen\/oeaf035","article-title":"The role of sphingolipids in heart failure","volume":"5","author":"Hamouche","year":"2025","journal-title":"Eur Heart J Open"},{"key":"B119","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12967-025-07661-2","article-title":"CTRP9 Ameliorates heart failure with preserved ejection fraction by regulating lipid metabolism","volume":"24","author":"Xin","year":"2026","journal-title":"J Transl Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/CIRCHEARTFAILURE.110.958785","article-title":"Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial","volume":"3","author":"Kitzman","year":"2010","journal-title":"Circ Heart Fail"},{"key":"B123","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"B124","doi-asserted-by":"publisher","first-page":"H424","DOI":"10.1152\/ajpheart.00529.2009","article-title":"Inhibition of transforming growth factor-beta signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart","volume":"298","author":"Lucas","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"952755","DOI":"10.3389\/fcvm.2022.952755","article-title":"AAV-mediated gene therapy: advancing cardiovascular disease treatment","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/HCO.0000000000000386","article-title":"Cardiac gene therapy with adeno-associated virus-based vectors","volume":"32","author":"Chamberlain","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1743-422X-10-50","article-title":"Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution","volume":"10","author":"Yang","year":"2013","journal-title":"Virol J"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1042\/CS20210052","article-title":"Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives","volume":"135","author":"Prakoso","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e82922","DOI":"10.1172\/jci.insight.82922","article-title":"Increased de novo ceramide synthesis and accumulation in failing myocardium","volume":"2","author":"Ji","year":"2017","journal-title":"JCI Insight"},{"key":"B130","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3390\/ijms26030995","article-title":"Spatial transcriptomics in human cardiac tissue","volume":"26","author":"Nguyen","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B131","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1002\/ehf2.15401","article-title":"Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials","volume":"12","author":"Araz","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 Receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B133","doi-asserted-by":"publisher","first-page":"116167","DOI":"10.1016\/j.isci.2026.116167","article-title":"The lysophosphatidylcholine-HIF-1alpha axis enhances apolipoprotein E sialylation and promotes electronegative LDL accumulation","volume":"29","author":"Chan","year":"2026","journal-title":"iScience"},{"key":"B134","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/biom9080386","article-title":"Proinflammatory action of a new electronegative low-density lipoprotein epitope","volume":"9","author":"Faulin","year":"2019","journal-title":"Biomolecules"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1649759","DOI":"10.3389\/fcvm.2025.1649759","article-title":"LDL Atherogenicity determined by size, density, oxidation, apolipoprotein(a), and electronegativity: an updated review","volume":"12","author":"Akyol","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/circ.152.suppl_3.4368942","article-title":"Electronegative VLDL drives maturity-dependent cellular dysfunction on human cardiomyocytes. In: 2025 American Heart Association scientific sessions - meeting abstract (4368942)","volume":"152","author":"Chiang","year":"2025","journal-title":"Circulation"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/circ.150.suppl_1.4144929","article-title":"Electronegative VLDL impairs mitochondrial function and promotes cardiomyocyte dysfunction in heart failure with preserved ejection fraction. In: 2024 American Heart Association scientific sessions - meeting abstract (4144929)","volume":"150","author":"Chiang","year":"2024","journal-title":"Circulation"},{"key":"B138","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.2174\/138161212802481219","article-title":"Inflammation in coronary artery disease and acute myocardial infarction - is the stage set for novel therapies?","volume":"18","author":"Klingenberg","year":"2012","journal-title":"Curr Pharm Des"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e70019","DOI":"10.1111\/eci.70019","article-title":"Evolving concepts of low-density lipoprotein: from structure to function","volume":"55","author":"Chen","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"B140","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcp.22783","article-title":"PAI-1 in tissue fibrosis","volume":"227","author":"Ghosh","year":"2012","journal-title":"J Cell Physiol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"B142","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cca.2021.10.018","article-title":"The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases","volume":"523","author":"Vural","year":"2021","journal-title":"Clin Chim Acta"},{"key":"B143","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11883-014-0428-y","article-title":"The underlying chemistry of electronegative LDL's Atherogenicity","volume":"16","author":"Ke","year":"2014","journal-title":"Curr Atheroscler Rep"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1885850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:43:41Z","timestamp":1785840221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1885850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":143,"alternative-id":["10.3389\/fcvm.2026.1885850"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1885850","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1885850"}}